Young women who were vaccinated against human papillomavirus (HPV) in their teens with an older GlaxoSmithKline product called Cervarix had up to an 87 percent lower risk of developing cervical cancer linked to the virus, a long-running English study found.
Covid-19 antibodies passed from infected mothers to their breastfeeding newborns provide more benefit to the baby than researchers expected to see, according to a report published on November 3 in JAMA Network Open. In other research, among people with impaired immune systems, some get less benefit than others from the mRNA Covid-19 vaccines while new data help clarify the differences and supports the need for extra shots.
Russia’s one-dose Sputnik Light vaccine had a good safety profile and induced strong immune responses especially in people who had already encountered Covid-19, according to the results of phase I and II trials published in The Lancet medical journal.
Prominent life sciences venture capital firm Flagship Pioneering announced a strategic partnership with the Cystic Fibrosis Foundation on November 3.
The U.S. Centers for Disease Control and Prevention issued a report that reviewed dozens of studies and the CDC’s own unpublished data on Covid-19 study concluding that immunity caused by natural Covid-19 infection and vaccines both lasted at least six months, but the immunity provided by the vaccines was more consistent.
The U.S. Food and Drug Administration extended Legend Biotech Corporation’s Prescription Drug User Fee Act (PDUFA) target date for the drug cilta-cel that the company is developing with partner Janssen Biotech to treat relapsed and/or refractory multiple myeloma.
Novartis forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.
Cambridge, Mass.-based Moderna and Emeryville, Calif.-based Metagenomi inked a strategic research and development deal on new gene editing systems for in vivo (in the body) human therapies.
Teva Pharmaceutical announced positive results from the company’s Phase III trial on a subcutaneous, long-acting injectable risperidone formulation in the treatment of schizophrenia.
Merck is widening the company’s reach into the treatment of autoimmune diseases by investing in Synthekine, a bioresearch company that develops engineered cytokine therapeutics.
